The U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered that all federal lawsuits alleging diabetic ketoacidosis (DKA) and kidney failure injuries from Invokana (canagliflozin) and Invokamet (canagliflozin and metformin) will be transferred to the District of New Jersey for pretrial handling.
Free Confidential Lawsuit Evaluation: If you or a loved one was injured by Invokana side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.
What’s the Problem?
According to court documents filed Dec. 7, 2016, Invokana and Invokamet lawsuits from districts in Illinois, Kentucky, Missouri, Minnesota, Virginia and West Virginia will be transferred to the District of New Jersey as part of a multidistrict litigation (MDL) to be overseen by Judge Brian R. Martinotti.
In May 2015, the U.S. Food & Drug Administration (FDA) issued a warning which stated that Invokana, Invokamet and other diabetes medications from the SGLT2 inhibitor class had been linked to kidney failure and diabetic ketoacidosis (also known as DKA, diabetic acidosis, metabolic ketoacidosis or ketoacidosis). DKA occurs when cells in the body are unable to get the glucose they need for energy, causing symptoms such as fatigue, confusion, difficulty breathing and frequent urination.
At the time of the filing, the MDL included about 55 lawsuits alleging that Invokana and Invokamet may cause a number of serious injuries, and that Janssen failed to adequately warn the public and medical community about these risks. The cases have enough similarity to consolidate for the sake of simplifying and expediting the litigation, according to the JPML.
“The actions share factual questions arising from allegations that taking Invokana or Invokamet may result in patients suffering various injuries, including diabetic ketoacidosis and kidney damage,” the Panel stated in its Transfer Order. “The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs.”
Studies show that in addition to Invokana and Invokamet, other diabetes medications from the SGLT2 inhibitor class may increase the risk of kidney failure and diabetic ketoacidosis. JPML is aware of at least 20 lawsuits involving injuries from Farxiga (dapagliflozin), Jardiance (empagliflozin), Glyxambi (empagliflozin and linagliptin) and Xigduo XR (dapagliflozin and metformin hydrochloride extended-release).
However, the New Jersey MDL is only for Invokana and Invokamet.
“Centralizing competing defendants in the same MDL may unnecessarily complicate case management, due to the need to protect trade secret and confidential information,” the Panel said.
Do I Have an Invokana Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Invokana lawsuits. We are handling individual litigation nationwide and currently accepting new diabetic ketoacidosis and kidney failure cases in all 50 states.
Free Case Evaluation: Again, if you were injured by Invokana side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.